Medicover AB/Skr MCOV B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Medicover AB
Medicover AB is a healthcare company that operates in the medical care and diagnostic services industry. It provides a wide range of healthcare services, including preventive care, specialist consultations, and surgeries, as well as laboratory and diagnostic tests. Founded in 1995, Medicover has developed a significant presence in Central and Eastern Europe, with its headquarters located in Stockholm, Sweden. The company strategically positions itself to offer both insurance services and healthcare services, allowing it to leverage synergies between these segments. It continues to expand its geographic footprint through acquisitions and organic growth, aiming to provide comprehensive healthcare solutions across its markets.
- Ticker
- Skr MCOV B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 49,000
- Headquarters
- Stockholm, Sweden
- Website
- www.medicover.com
Medicover AB Metrics
BasicAdvanced
kr 43B
46.07
kr 6.15
1.50
kr 2.17
0.77%
Price and volume
Market cap
kr 43B
Beta
1.5
52-week high
kr 284.50
52-week low
kr 179.40
Average daily volume
79K
Dividend rate
kr 2.17
Financial strength
Current ratio
0.55
Quick ratio
0.481
Long term debt to equity
1.559
Total debt to equity
2.642
Dividend payout ratio (TTM)
35.57%
Interest coverage (TTM)
2.71%
Profitability
EBITDA (TTM)
3,062.58
Gross margin (TTM)
23.37%
Net profit margin (TTM)
3.44%
Operating margin (TTM)
7.18%
Effective tax rate (TTM)
26.31%
Revenue per employee (TTM)
kr 548,260
Management effectiveness
Return on assets (TTM)
4.66%
Return on equity (TTM)
15.49%
Valuation
Price to earnings (TTM)
46.072
Price to revenue (TTM)
1.584
Price to book
80.26
Price to tangible book (TTM)
-154.15
Price to free cash flow (TTM)
20.977
Free cash flow yield (TTM)
4.77%
Free cash flow per share (TTM)
13.515
Dividend yield (TTM)
0.77%
Forward dividend yield
0.77%
Growth
Revenue change (TTM)
9.28%
Earnings per share change (TTM)
94.43%
3-year revenue growth (CAGR)
15.29%
3-year earnings per share growth (CAGR)
149.49%
3-year dividend per share growth (CAGR)
18.56%
What the Analysts think about Medicover AB
Analyst ratings (Buy, Hold, Sell) for Medicover AB stock.
Analyst projections of the future price of Medicover AB stock.
Bulls say / Bears say
Medicover delivered 11.8% organic revenue growth in Q2 2026, while EBIT rose 22.6% and the operating margin reached 8.0%. Operating cash flow also increased, giving the company more room to fund growth. (MFN.se)
Diagnostics is a strong growth and profit driver: its Q2 organic revenue grew 10.9%, while its margin rose to 18.8%. Higher fee-for-service revenue and a richer mix of advanced tests supported that improvement. (MFN.se)
The planned India sale could improve the group’s financial flexibility: India accounts for about 9% of sales but only 3% of EBIT and makes a net loss, according to Inderes. It estimates post-deal net debt near zero, leaving cash available for acquisitions in Medicover’s core markets. (Inderes)
Selling the Indian business removes Medicover’s fastest-growing unit. SB1 expects organic growth to slow to 7–9% after the sale and has cut its sales forecasts for 2027 and 2028. (Börsvärlden)
Romania is a persistent pressure point: political uncertainty, high inflation and a weaker labour market are weighing on member and revenue growth. Inderes says these pressures may last and has trimmed its growth expectations for Healthcare Services. (Inderes)
Valuation may leave limited room for disappointment. After the India-sale announcement, the shares had risen about 20%, and SB1 valued the remaining business at 18 times 2027 EV/EBITA when it cut its rating to neutral. (Börsvärlden)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
Medicover AB Financial Performance
Revenues and expenses
Medicover AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Medicover AB
Fund name | Fund size | Skr MCOV B weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.19% |
iShares Ageing Population€AGED | $903M | 0.19% |
iShares Ageing Population£AGES | $953M | 0.19% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.12% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.